In vivo studies by Nan et al. and Chen et al. confirmed that XGND can significantly reduce the mRNA and proteins expression levels of NF-κB and NF-κB p65 in nasal mucosa of AR guinea pigs and reduce the concentrations of inflammatory factors such as IL-5, GM-CSF, and CCL-1 in serum and nasal lavage fluid, suggesting that XGND can also restrain the allergic reaction by inhibiting the activation and nuclear translocation of NF-κB and weakening the biological effects of IL-5, GM-CSF, CCL1, and other inflammatory factors [19, 20]. The gene discussed is CCL1; the disease is allergic disease.